Editas Medicine Inc
EDIT2.595USD
+0.155+6.35%
Horário de mercado （ET）Cotações atrasadas em 15 min
217.23MValor de mercado
PerdaP/L TTM
Mais detalhes de Editas Medicine Inc Empresa
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Informações da empresa
Código da empresaEDIT
Nome da EmpresaEditas Medicine Inc
Data de listagemFeb 03, 2016
CEODr. Gilmore O'Neill
Número de funcionários246
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 03
Endereço11 Hurley St
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02141-2110
Telefone16174019000
Sitehttps://www.editasmedicine.com/
Código da empresaEDIT
Data de listagemFeb 03, 2016
CEODr. Gilmore O'Neill
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
Independent Director
Independent Director
--
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 7 de jun
Atualizado em: sáb, 7 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
Tipos de investidores
Investidores
Proporção
Investment Advisor
30.95%
Investment Advisor/Hedge Fund
12.97%
Research Firm
6.63%
Hedge Fund
5.44%
Bank and Trust
0.80%
Venture Capital
0.57%
Individual Investor
0.33%
Family Office
0.21%
Pension Fund
0.04%
Other
42.06%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
526
48.45M
57.87%
-23.30M
2025Q1
560
48.21M
57.60%
-23.68M
2024Q4
576
55.95M
67.78%
-11.28M
2024Q3
585
59.63M
72.30%
-8.64M
2024Q2
584
60.69M
73.86%
-19.13M
2024Q1
583
72.72M
88.97%
+367.05K
2023Q4
602
63.06M
77.30%
-13.98M
2023Q3
641
65.84M
80.91%
-11.78M
2023Q2
659
66.65M
82.05%
-208.12K
2023Q1
669
56.55M
82.00%
-9.39M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
7.47M
8.92%
+643.26K
+9.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.08M
7.26%
-551.77K
-8.32%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.55M
3.05%
+1.36M
+113.76%
Mar 31, 2025
Two Sigma Investments, LP
2.46M
2.94%
-841.30K
-25.45%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.94M
2.32%
+135.21K
+7.48%
Mar 31, 2025
State Street Global Advisors (US)
1.85M
2.21%
-26.11K
-1.39%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.61M
1.92%
-551.03K
-25.52%
Mar 31, 2025
UBS Asset Management (Switzerland)
1.60M
1.91%
+430.00K
+36.75%
Mar 31, 2025
BofA Global Research (US)
1.52M
1.81%
+1.08M
+250.36%
Mar 31, 2025
UBS Asset Management Switzerland AG
1.17M
1.4%
+1.17M
--
Jan 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
WisdomTree BioRevolution Fund
1.56%
Invesco NASDAQ Future Gen 200 ETF
0.58%
AXS Green Alpha ETF
0.29%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Ver Mais
WisdomTree BioRevolution Fund
Proporção1.56%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.58%
AXS Green Alpha ETF
Proporção0.29%
iShares Micro-Cap ETF
Proporção0.03%
Invesco Nasdaq Biotechnology ETF
Proporção0.02%
iShares Biotechnology ETF
Proporção0.02%
ProShares Ultra Nasdaq Biotechnology
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
